Head-To-Head Comparison: Definium Therapeutics (NASDAQ:DFTX) versus Takara Bio (OTCMKTS:TKBIF)

Definium Therapeutics (NASDAQ:DFTX) and Takara Bio (OTCMKTS:TKBIF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Institutional & Insider Ownership

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.3% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Definium Therapeutics and Takara Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-86.18%	-62.29%
Takara Bio	N/A	N/A	N/A

Valuation & Earnings

This table compares Definium Therapeutics and Takara Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$108.68 million	($2.04)	-8.64
Takara Bio	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Definium Therapeutics and Takara Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1	0	10	2	3.00
Takara Bio	0	0	0	0	0.00

Definium Therapeutics presently has a consensus target price of $34.20, indicating a potential upside of 94.10%. Given Definium Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Definium Therapeutics is more favorable than Takara Bio.

Summary

Definium Therapeutics beats Takara Bio on 6 of the 8 factors compared between the two stocks.

About Definium Therapeutics

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

About Takara Bio

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.